Clinuvel Pharmaceuticals Ltd (CLVLF)
Market Closed
7 Aug, 20:00
$
6. 54
0
0%
$
343.8M Market Cap
- P/E Ratio
- Div Yield
1,500 Volume
- Eps
$ 6.54
Previous Close Want to track CLVLF and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
CLVLF closed Friday higher at $6.54, an increase of 0% from Thursday's close, completing a monthly increase of 7.2131% or $0.44. Over the past 12 months, CLVLF stock lost -15.0649%.
CLVLF pays dividends to its shareholders, with the most recent payment made on Sep 19, 2025. The next estimated payment will be in In 1 month on Sep 19, 2026 for a total of $0.0327.
The last earnings report, released on Feb 24, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Clinuvel Pharmaceuticals Ltd has completed 2 stock splits, with the recent split occurring on Nov 18, 2010.
The company's stock is traded on 7 different exchanges and in various currencies, with the primary listing on ASX (AUD).
Clinuvel Pharmaceuticals Ltd (CLVLF) FAQ
What is the stock price today?
The current price is $6.54.
On which exchange is it traded?
Clinuvel Pharmaceuticals Ltd is listed on OTC PINK.
What is its stock symbol?
The ticker symbol is CLVLF.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 343.8M.
Has Clinuvel Pharmaceuticals Ltd ever had a stock split?
Clinuvel Pharmaceuticals Ltd had 2 splits and the recent split was on Nov 18, 2010.
Clinuvel Pharmaceuticals Ltd Profile
| Biotechnology Industry | Healthcare Sector | Dr. Philippe Jacques Wolgen M.B.A., M.D. CEO | OTC PINK Exchange | AU000000CUV3 ISIN |
| AU Country | - Employees | 4 Sep 2025 Last Dividend | 12 Nov 2010 Last Split | - IPO Date |
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone for targeting neurological, endocrinological, and degenerative disorders; and pharmaceutical formulations melanocortin technology for the treatment of a range of disorders. In addition, the company provides photocosmetic products for individuals and populations at risk of exposure to ultraviolet and high energy visible light, and in need of assistance in DNA repair and melanogenesis of the skin. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.
Contact Information
Address: 535 Bourke Street, Melbourne, VIC, Australia, 3000
Phone: 61 3 9660 4900
Website: https://www.clinuvel.com
